Comparisons

    Compare GLP-1 Weight Loss Medications

    Make informed decisions with detailed, evidence-based comparisons of all available GLP-1 medication options.

    Understanding Your Options

    With multiple GLP-1 medications available, choosing the right one can feel overwhelming. This hub provides comprehensive comparisons to help you understand the differences in efficacy, side effects, dosing schedules, and costs.

    15-22%
    Average Weight Loss Range
    5+
    FDA-Approved Options
    $900-1,500
    Monthly Cost Range

    In-Depth Comparisons

    Quick Comparison Overview

    FeatureSemaglutideTirzepatide
    Average Weight Loss15-17%20-22%
    Dosing FrequencyOnce weeklyOnce weekly
    MechanismGLP-1 agonistGLP-1/GIP dual agonist
    Average Cost/Month$900-1,200$1,000-1,500
    Common Side EffectsNausea, diarrheaNausea, diarrhea

    Find Your Perfect Match

    Talk to a Trimi healthcare provider to determine which GLP-1 medication is best suited for your unique needs and health goals.

    Get Personalized Recommendations

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    How do I compare GLP-1 weight-loss providers and medications?

    Compare GLP-1 telehealth providers across five dimensions: (1) price — sticker rate plus billing tier (annual vs monthly), (2) US-licensed prescribing clinicians, (3) FDA-registered pharmacy with publicly verifiable state-board record, (4) active-ingredient disclosure (whether the medication is brand or compounded, and what active ingredient is delivered), (5) state coverage matching where you live. Lowest published cash-pay rates in May 2026: Trimi Health $99/month for compounded semaglutide on annual billing ($1,188/year), $125/month for compounded tirzepatide on annual billing ($1,500/year). Compare to: Henry Meds $129/$179, Mochi $135/$229, Sequence/Form $179/$329, Hims $199/$329. Brand vs compounded: same active ingredient, different regulatory status — brand Wegovy/Ozempic/Zepbound/Mounjaro are FDA-approved as drugs (~$998-$1,349/month retail); compounded versions are prepared per individual prescription at FDA-registered 503A sterile-compounding pharmacies (not FDA-approved as drugs). All comparison articles on this hub use the same framework so cross-comparison is consistent.

    Compare on: price, clinicians, pharmacy, active-ingredient, state coverage.
    Cheapest cash-pay: Trimi $99 sema, $125 tirz annual.
    Brand cash-pay: $998-$1,349/mo. Compounded: $99-$199/mo.

    Key Takeaways

    • GLP-1 telehealth comparison framework: evaluate providers on price, US-licensed prescribing clinicians, FDA-registered pharmacy with public state-board record, active-ingredient disclosure, and state coverage.
    • Lowest published cash-pay rates (May 2026): Trimi Health $99/month sema annual / $125/month tirz annual; Henry Meds $129/$179; Mochi $135/$229.
    • Brand vs compounded comparison: same active ingredient (semaglutide or tirzepatide) but different regulatory status — brands FDA-approved as drugs, compounded prepared per individual prescription at 503A pharmacies (not FDA-approved as drugs).
    • Insurance vs cash-pay: brand medications via insurance can be as low as $25/month with savings cards; without insurance, compounded telehealth at $99-$199/month is consistently cheaper than brand cash-pay ($998-$1,349/month).
    • All major comparisons on this hub use the same evaluation framework so cross-comparison is fair.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 15, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. U.S. Food and Drug Administration (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA.Read Study
    2. U.S. Food and Drug Administration (2026). BeSafeRx: Your Source for Online Pharmacy Information. FDA.Read Study
    3. National Association of Boards of Pharmacy (2026). Buy Safely. NABP.Read Study

    Was this article helpful?

    Keep Reading

    Updated 2025 comparison of tirzepatide vs semaglutide. Latest clinical data on weight loss, side effects, cost, and which GLP-1 medication is right for you.

    Four-way comparison of the most prescribed weight loss medications in 2026. Compare efficacy, side effects, cost, duration of use, and who each drug is best for.

    New SURMOUNT-5 data confirms tirzepatide outperforms semaglutide 20.2% vs 13.7% weight loss. A complete 2026 head-to-head on efficacy, side effects, and cost.

    GLP-1 Medications

    How Retatrutide Works

    Retatrutide produced up to 24% weight loss in Phase 2 trials. See dose-response data, comparison with semaglutide and tirzepatide, timeline projections, and FDA approval outlook.

    Start your GLP-1 journey — from $99/mo

    Get Started